List of Excipients in Branded Drug DICLOFENAC SODIUM TOPICAL GEL 1%

« Back to Dashboard

Generic Drugs Containing DICLOFENAC SODIUM TOPICAL GEL 1%

Company	Ingredient	NDC	Excipient
Walgreens Company	diclofenac sodium topical gel, 1%	0363-7065	AMMONIA
Walgreens Company	diclofenac sodium topical gel, 1%	0363-7065	CARBOMER HOMOPOLYMER TYPE C
Walgreens Company	diclofenac sodium topical gel, 1%	0363-7065	COCO-CAPRYLATE/CAPRATE
Walgreens Company	diclofenac sodium topical gel, 1%	0363-7065	ISOPROPYL ALCOHOL

What are the Most Frequently-Used Excipients in DICLOFENAC SODIUM TOPICAL GEL 1%?

# Of NDCs	Excipient
2	AMMONIA
2	CARBOMER HOMOPOLYMER TYPE C
2	COCO-CAPRYLATE/CAPRATE
2	ISOPROPYL ALCOHOL

Diclofenac Sodium Topical Gel 1%: Excipient Strategy, Patent Risk and Commercial Opportunities

Last updated: September 26, 2026

Diclofenac sodium topical gel 1% is a mature, high-volume topical NSAID market with low active-ingredient cost and meaningful formulation barriers. The leading commercial product, Voltaren Arthritis Pain, uses a hydroalcoholic gel system designed to solubilize diclofenac sodium, improve skin delivery, control viscosity, and provide acceptable sensory performance. The strongest opportunities are differentiated generic products, private-label OTC products, preservative or alcohol-reduced formulations, improved packaging, and region-specific versions for pain, osteoarthritis, and sports-injury markets.

The key commercial constraint is regulatory sameness. A product that departs materially from the reference formulation may require more extensive formulation, performance, and clinical evidence. Patent risk is lower than it was during the original prescription launch period, but formulation know-how, regulatory exclusivity, trademarks, device configuration, and market access remain important.

What is diclofenac sodium topical gel 1%?

Diclofenac sodium topical gel 1% contains 10 mg of diclofenac sodium per gram of gel. In the United States, the product is used for temporary relief of arthritis pain in joints suitable for topical treatment. Voltaren Arthritis Pain transitioned from prescription to nonprescription status through an FDA-approved supplemental application associated with NDA 022122 in 2020. The product remains an FDA-approved drug product rather than a product marketed solely under the OTC monograph system (FDA, 2020a).

Diclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin production. Topical administration is intended to produce local exposure while reducing systemic exposure relative to oral diclofenac, although systemic absorption and NSAID class warnings remain relevant.

Reference formulation and excipient functions

The marketed Voltaren formulation has used the following functional excipient classes:

Excipient or excipient class	Primary function
Carbomer homopolymer	Gel structure, viscosity and suspension stability
Diethylene glycol monoethyl ether	Solvent and penetration enhancer
Isopropyl alcohol	Solvent, drying and sensory modification
Propylene glycol	Cosolvent and humectant
Cocoyl caprylocaprate	Emollient and skin-feel modifier
Liquid paraffin	Emolliency and occlusivity
Polyoxyl 20 cetostearyl ether	Surfactant and solubilization support
Purified water	Continuous phase

The commercial formulation is a balance among drug solubility, thermodynamic activity, skin permeability, drying time, spreadability, viscosity, irritation, and consumer acceptance. Changing one component can affect several performance attributes at once.

What excipient strategy is optimal for diclofenac sodium gel 1%?

The optimal strategy is to preserve the reference product’s critical performance profile while creating a defensible improvement in one commercial attribute. The most attractive attributes are lower residue, reduced odor, faster drying, lower irritation, improved dosing accuracy, and better stability after opening.

1. Solubilization and thermodynamic activity

Diclofenac sodium is an ionizable drug. Its apparent solubility and skin partitioning depend on pH, solvent composition, ionic strength, and the balance between fully dissolved drug and drug activity at the skin interface.

A formulation with excessive solvent can improve initial solubility but reduce thermodynamic activity if the drug remains too comfortably solubilized. A formulation with insufficient solvent may produce crystallization, inconsistent dose delivery, or poor physical stability.

Development should characterize:

• Diclofenac sodium solubility across the target pH range.
• Drug crystallization after temperature cycling.
• Solvent evaporation during use.
• Drug activity in the final gel.
• Compatibility with packaging materials.
• Changes in viscosity and assay over shelf life.

Diethylene glycol monoethyl ether, commonly known as Transcutol, is strategically important because it can improve solubilization and skin permeation. Alternatives include propylene glycol, polyethylene glycol systems, ethanol, isopropanol, and selected glycol ethers. Each alternative changes irritation potential, evaporation, odor, and regulatory positioning.

2. Rheology and application performance

Carbomer is the conventional gel-forming polymer for this product type. Its concentration, neutralization, grade, and interaction with salts determine viscosity and yield stress.

The target rheology must allow the product to:

• Exit the tube or pump consistently.
• Spread over an osteoarthritic joint without excessive rubbing.
• Remain in place after application.
• Resist phase separation.
• Deliver a reproducible amount per dose.
• Avoid stringiness and pilling under clothing.

Potential polymer alternatives include acrylates crosspolymers, cellulose derivatives, poloxamers, and associative thickeners. These alternatives may produce commercial differentiation, but they can complicate comparability because polymer substitution affects drug release, skin permeation, drying, and sensory characteristics.

3. Penetration-enhancer selection

Penetration enhancement is a central formulation decision. The excipient system must improve delivery through the stratum corneum without causing unacceptable irritation.

Candidate approaches include:

Approach	Potential benefit	Principal risk
Glycol ether systems	Strong solvent and penetration performance	Irritation and regulatory scrutiny
Alcohol-containing systems	Rapid drying and initial permeation	Stinging, dryness and flammability labeling
Propylene glycol	Broad regulatory familiarity	Tackiness and irritation at higher levels
Fatty esters	Improved skin feel and emolliency	Occlusivity, phase behavior and slower drying
Terpenes or essential-oil components	Permeation enhancement and sensory differentiation	Irritation, odor and allergen concerns
Lipid or nanoemulsion systems	Potential delivery and cosmetic advantages	More complex manufacturing and characterization

The best commercial opportunity is usually not the most aggressive penetration system. It is a system that delivers comparable performance with better tolerability and a more acceptable user experience.

4. Preservatives and microbiological control

Aqueous gels require a microbiological-control strategy. Alcohol content may contribute to preservation, but it should not be assumed to provide complete protection under all packaging and use conditions.

Options include:

• A conventional preservative system.
• Alcohol-assisted preservation.
• Reduced-water or anhydrous systems.
• Airless packaging.
• Single-use or unit-dose formats.
• Preservative-free systems supported by validated manufacturing and packaging controls.

Preservative-free products can create a differentiated premium position, particularly for consumers with sensitive skin. They also increase manufacturing, container-closure, and microbial-control requirements. Preservative changes may affect regulatory comparability and should be treated as a core product-development variable rather than a cosmetic adjustment.

What formulations are protected by diclofenac sodium gel patents?

The original prescription product was supported by formulation and topical-delivery patent activity, but the commercially relevant United States protection for the original 1% diclofenac gel has largely aged beyond its primary exclusivity period. Current competition is therefore driven less by broad composition-of-matter protection and more by product-specific formulation claims, device claims, method-of-use claims, trademarks, regulatory status, and manufacturing know-how.

Patent review should distinguish among four categories:

1. Composition patents: Claims directed to diclofenac, salts, solvates, or broad topical compositions.
2. Formulation patents: Claims directed to particular solvent, polymer, surfactant, penetration-enhancer, pH, or viscosity combinations.
3. Method-of-use patents: Claims directed to treating osteoarthritis or other pain conditions with topical diclofenac.
4. Packaging and device patents: Claims directed to metered pumps, applicators, tubes, dosing aids, or delivery systems.

The original active ingredient is not a durable barrier. New patent value would need to come from a specific formulation, delivery device, manufacturing process, or new therapeutic use with credible claim scope.

What is the Orange Book status of diclofenac sodium topical gel 1%?

The FDA Orange Book is relevant to approved prescription NDAs and their listed patents. Voltaren Gel was approved under NDA 022122. The later OTC product was authorized through an FDA supplemental application and is sold under the Voltaren Arthritis Pain brand.

For commercial planning, the principal distinction is:

Issue	Commercial implication
Prescription NDA	Relevant to historical Orange Book listings and ANDA pathways
OTC supplemental approval	Direct-to-consumer positioning and broader retail distribution
OTC monograph status	Diclofenac gel is not simply an OTC-monograph product; approved NDA documentation remains important
Generic pathway	A competing product may require an ANDA or another FDA-approved pathway depending on labeling and formulation
Trademark	Brand recognition can remain commercially important after patent expiry

An OTC switch does not eliminate the need to evaluate the reference product’s labeling, formulation, manufacturing controls, and applicable FDA product-specific guidance.

When does diclofenac sodium topical gel lose exclusivity?

The principal market exclusivity associated with the original product has already passed in the United States. The exact commercial opening depends on the relevant patents, pediatric exclusivity, regulatory exclusivity, formulation differences, and the legal status of any specific product.

For small-molecule topical products, the practical loss of exclusivity often occurs in stages:

Stage	Commercial effect
Core active-ingredient patents expire	Broad chemical protection ends
Primary formulation patents expire	Formulation-focused entry becomes more feasible
Regulatory exclusivity expires	ANDA or other competing approvals face fewer blocking periods
OTC switch occurs	Retail access expands and brand demand increases
Multiple generic entries launch	Price competition and retailer substitution intensify
Brand remains differentiated	Packaging, advertising, distribution and consumer trust support premium pricing

Patent expiration does not guarantee immediate generic launch. Topical products can require substantial equivalence, manufacturing, and performance development even when legal exclusivity has ended.

How strong is the patent estate for diclofenac sodium topical gel 1%?

The estate is moderate to weak for the original broad product concept and stronger for narrowly defined improvements.

Stronger protection areas

• A novel formulation with demonstrated superiority in permeation or tolerability.
• A specific polymer-solvent system with unexpected stability or delivery results.
• A metered-dose applicator that improves dose accuracy.
• A manufacturing process that prevents crystallization or improves content uniformity.
• A new indication supported by clinical evidence.
• A combination product with a separate active ingredient and validated benefit.

Weaker protection areas

• Routine substitution of one solvent for another.
• Minor concentration adjustments without unexpected results.
• Conventional carbomer gels with standard alcohol and glycol systems.
• Broad claims covering diclofenac in a topical vehicle.
• Cosmetic changes that do not alter drug delivery or clinical performance.

A formulation patent should be evaluated against prior art for diclofenac gels, topical NSAIDs, carbomer systems, hydroalcoholic vehicles, penetration enhancers, and transdermal delivery systems. Patent strength depends on claim construction and experimental support, not on the number of cited excipients.

What FDA regulatory pathway applies to competing products?

A generic prescription version generally follows the ANDA pathway if it can demonstrate the required equivalence to the reference listed drug. Topical products raise more complex equivalence issues than conventional immediate-release tablets.

Relevant evidence can include:

• Q1 qualitative sameness of inactive ingredients.
• Q2 quantitative sameness within applicable FDA expectations.
• Comparative physicochemical characterization.
• In vitro release testing.
• In vitro permeation testing.
• Comparative product performance.
• Adhesion, spreadability, viscosity and rheology data.
• Drug content uniformity and microbial limits.
• Comparative clinical endpoint data when required.

FDA product-specific guidance for topical products has increased the importance of formulation sameness and performance testing. A formulation that is commercially attractive but materially different from the reference product may move from a relatively efficient generic strategy toward a more expensive 505(b)(2) or standalone NDA strategy (FDA, 2023).

No biosimilar pathway applies. Diclofenac sodium is a chemically synthesized small molecule, not a biologic. Biosimilar risk is therefore zero for this product category, although competing topical NSAIDs and generic oral NSAIDs remain relevant substitutes.

What generic entry risks exist for Voltaren Arthritis Pain?

The largest risks are substitution, private-label competition, retailer bargaining power, and formulation commoditization.

Generic launch scenarios

Scenario	Likely market effect
One or two prescription generics	Moderate price erosion; brand retains OTC consumer demand
Multiple generic 1% gels	Strong pharmacy substitution and payer pressure
Private-label OTC launches	Retail price compression and shelf-space competition
Premium reformulations	Market segmentation rather than direct price competition
Pump or airless-pack competitors	Potential differentiation through convenience and dosing
Lower-cost regional products	Increased pressure in price-sensitive international markets

The OTC market can protect a brand from complete generic erosion because consumers purchase through retailers rather than relying exclusively on pharmacy substitution. Brand recognition, advertising, retailer relationships, and packaging can be more important than patent status after launch.

What excipient innovations create commercial opportunities?

The most credible opportunities are product improvements that consumers can recognize and regulators can measure.

Lower-irritation gel

A lower-alcohol or alcohol-free product could target users who experience dryness or stinging. The formulation must preserve drug release and skin delivery while controlling microbial risk and drying time.

Fast-drying gel

A faster-drying system can reduce transfer to clothing and improve adherence. The tradeoff is greater solvent evaporation, potential skin irritation, and the risk of drug crystallization after application.

Non-greasy or low-residue gel

Reducing liquid paraffin or changing the emollient system can improve cosmetic acceptability. This approach is useful for daytime use and for consumers who dislike occlusive products.

Pump or metered-dose packaging

A pump can improve dose reproducibility, reduce hand contamination, and support premium positioning. Packaging must protect the formulation from evaporation and maintain pump function as viscosity changes.

Preservative-free presentation

A preservative-free gel could target sensitive-skin consumers. Airless packaging, unit-dose packs, or validated low-water systems may support this claim, but the development burden is higher.

Combination pain products

Combining diclofenac with counterirritants, cooling agents, or complementary analgesic ingredients could produce a differentiated product. Such products introduce new safety, labeling, compatibility, and regulatory requirements and may not fit a conventional generic pathway.

Regional formulation platforms

Markets differ in permitted excipients, consumer preferences, climate, and regulatory pathways. A platform using carbomer, propylene glycol, and a broadly accepted solvent system can support multiple regional versions with limited reformulation.

Which companies are competing in diclofenac topical gel?

The competitive field includes:

• Haleon, through Voltaren Arthritis Pain.
• Generic pharmaceutical companies selling diclofenac sodium gel.
• Contract manufacturers supplying private-label topical NSAIDs.
• Regional pharmaceutical companies in Europe, Asia, Latin America, and the Middle East.
• Specialty topical-drug developers pursuing improved delivery systems.

Competition is fragmented because diclofenac gel is relatively simple to manufacture compared with transdermal patches, liposomal systems, or biologic products. The commercial advantage shifts toward scale, retailer access, regulatory execution, packaging, and cost control.

How does diclofenac gel compare with competing topical NSAIDs?

Product category	Main advantage	Main limitation
Diclofenac sodium gel 1%	Established efficacy, broad recognition and mature supply chain	Crowded market and limited active-ingredient differentiation
Diclofenac epolamine topical systems	Alternative salt and delivery formats	More complex dosage forms and regional availability
Diclofenac solution products	Potentially simple application and rapid drying	Different dosing and sensory profile
Topical ketoprofen	Established topical NSAID use in some markets	Phototoxicity concerns in certain jurisdictions
Topical ibuprofen	Familiar active ingredient	Different regulatory and clinical positioning
Capsaicin products	Non-NSAID mechanism and long-lasting effect	Burning sensation and different patient acceptance
Menthol or counterirritant gels	Strong sensory effect and OTC accessibility	Limited anti-inflammatory positioning

Diclofenac gel benefits from a strong evidence base and consumer awareness, but those same attributes attract generic and private-label competition.

What manufacturing and IP barriers matter?

Manufacturing is not technically prohibitive, but quality control can determine commercial success. Key process risks include:

• Carbomer hydration and neutralization.
• Entrapped air and filling variability.
• Drug crystallization during storage.
• Solvent evaporation during manufacture and packaging.
• Content uniformity across the batch.
• Viscosity drift with temperature and pH.
• Container-closure compatibility.
• Preservative distribution.
• Pump dose variability.
• Stability after repeated opening.

The most defensible manufacturing know-how concerns crystallization control, scale-up, order of addition, deaeration, filling, and packaging. These controls may not create broad patent protection, but they can reduce failed batches and support reliable supply.

What is the commercial revenue exposure?

Voltaren is a significant global consumer-health brand, but product-level revenue is generally reported by brand or category rather than by exact presentation in public company filings. Revenue exposure depends on:

• OTC retail penetration.
• Prescription-to-OTC conversion.
• Market share against store brands.
• Average retail price.
• Reimbursement and pharmacy substitution.
• Geographic mix.
• Seasonal pain demand.
• Advertising expenditure.
• Retailer private-label strategy.

For an entrant, the opportunity is more attractive when the product is paired with a differentiated package, a lower cost of goods, or a strong regional distribution agreement. A plain me-too gel competes primarily on price and supply reliability.

What licensing deals are relevant to diclofenac sodium gel?

Licensing opportunities are most likely in four areas:

1. Regional commercialization rights for markets where the current brand has limited distribution.
2. Private-label supply agreements with pharmacy chains, supermarkets, and e-commerce retailers.
3. Delivery technology licensing involving pumps, airless containers, microemulsions, or low-irritation vehicles.
4. Contract development and manufacturing agreements for companies that lack topical-gel production capacity.

The strongest deal assets are regulatory-ready formulations, validated manufacturing processes, approved regional products, and packaging systems with measurable consumer benefits. A formulation concept without equivalence or stability data has limited licensing value.

What litigation and Paragraph IV risks affect the market?

Paragraph IV exposure is product-specific. A generic applicant may challenge listed patents by asserting that patents are invalid, unenforceable, or not infringed. The commercial effect depends on whether the product is prescription, OTC, or a different formulation with a separate approval pathway.

The principal litigation questions are:

• Which patents were listed for the relevant reference product?
• Are the claims directed to the gel composition, method of use, or packaging?
• Does the proposed product use the same inactive ingredients?
• Is a Paragraph IV notice required?
• Is a 30-month stay available?
• Does the proposed label carve out patented uses?
• Does the product qualify for 180-day generic exclusivity?

Because patent status can change through delisting, expiration, settlement, or court decisions, litigation analysis must be tied to a specific applicant and filing date. No biosimilar litigation framework applies.

Key takeaways

• Diclofenac sodium topical gel 1% is a mature small-molecule topical market with substantial OTC demand.
• The formulation depends on a coordinated solvent, penetration-enhancer, polymer, emollient, and packaging system.
• The strongest product opportunities are lower-irritation, faster-drying, low-residue, preservative-free, and metered-dose presentations.
• Broad original-product patent protection is less important than formulation-specific claims, trademarks, regulatory execution, manufacturing know-how, and retail access.
• Generic and private-label competition can compress price, but strong consumer branding can preserve premium positioning.
• Topical equivalence is more demanding than simple oral-tablet substitution.
• Diclofenac products do not face biosimilar competition because diclofenac is a synthetic small molecule.
• Licensing value is highest for approved or near-approval formulations, validated manufacturing processes, and differentiated delivery systems.

FAQs about diclofenac sodium topical gel 1%

Is diclofenac sodium gel 1% the same as Voltaren Arthritis Pain?

It contains the same active ingredient and strength, but excipients, packaging, labeling, manufacturing site, and regulatory status can differ. Therapeutic equivalence depends on the specific product and FDA approval pathway.

Can a preservative-free diclofenac gel be marketed as a generic?

Potentially, but a materially different excipient system may require additional formulation and performance evidence. Preservative-free status alone does not establish equivalence.

Which excipient most affects diclofenac skin penetration?

The solvent and penetration-enhancer system generally has the greatest effect, but polymer concentration, pH, emollients, and drug activity also materially influence permeation.

Is a diclofenac gel pump patentable?

A pump can support patent claims if it has a novel structure, dose-control mechanism, compatibility feature, or functional interaction with the gel. A conventional pump substitution is less likely to provide strong protection.

Can diclofenac sodium gel be sold under the OTC monograph?

In the United States, diclofenac sodium gel 1% is associated with an FDA-approved product pathway rather than reliance solely on the traditional OTC topical analgesic monograph. Product-specific approval and labeling requirements remain central.

References

1. U.S. Food and Drug Administration. (2020a). Voltaren Arthritis Pain topical gel 1%: Prescribing information and labeling materials. FDA.

2. U.S. Food and Drug Administration. (2020b). FDA approves first over-the-counter topical nonsteroidal anti-inflammatory drug for arthritis pain. FDA.

3. U.S. Food and Drug Administration. (2023). Product-specific guidance for generic drug development: Diclofenac sodium topical gel, 1%. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. Haleon plc. (2024). Annual report and financial statements 2023. Haleon.

6. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.